可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 何继强, 王绿娅, 刘晓惠. 血管紧张素II与动脉粥样硬化形成的研究进展[J]. 中国动脉硬化杂志, 2004, 12(3): 360-362.
[2] Gross CM, Gerbaulet S, Quensel C, et al. Angiotensin II type 1 receptor expression in human coronary arteries with variable degrees of atherosclerosis[J]. Basic Res Cardiol, 2002, 97(4): 327-333.
[3] Rueckschloss U, Quinn MT, Holtz J, et al. Dosedependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease[J]. Arterioscler Thromb Vasc Biol, 2002, 22(11): 1845-1851.
[4] Cathcart MK. Regulation of superoxide anion production by NAD(P)H oxidase in monocytes/macrophages: contributions to atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2004, 24(1): 23-28.
[5] 林燕, 黄维义, 李著华. 氧化应激致动脉粥样硬化作用的研究进展[J]. 黑龙江医学, 2004, 28(7): 517-519.
[6] Ross R. Atherosclerosis——an inflammatory disease[J]. N Engl J Med,1999,340(2):115-126.
[7] Yamaguchi Y, Kunitomo M, Haginaka J. Assay methods of modified lipoproteins in plasma[J] . J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 781(1-2): 313-330.
[8] Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of Nitric Oxide in patients with coronary artery disease: Role of superoxide dismutase[J]. Circulation, 2001, 103(6): 799-805.
[9] Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis[J]. Am J Hypertens, 2002, 15(1 pt 2): 9s-13s.
[10]Fennessy PA, Campbell JH, Mendelsohn FA, et al. Angiotensinconverting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease[J]. Clin Exp Pharmacol Physiol, 1996, 23(8):S30-S32.